Literature DB >> 21864598

Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

Claire J Forbes1, Deborah Lowry, Leslie Geer, Ronald S Veazey, Robin J Shattock, Per Johan Klasse, Mark Mitchnick, Laurie Goldman, Lara A Doyle, Brendan C O Muldoon, A David Woolfson, John P Moore, R Karl Malcolm.   

Abstract

Aqueous semi-solid polymeric gels, such as those based on hydroxyethylcellulose (HEC) and polyacrylic acid (e.g. Carbopol®), have a long history of use in vaginal drug delivery. However, despite their ubiquity, they often provide sub-optimal clinical performance, due to poor mucosal retention and limited solubility for poorly water-soluble actives. These issues are particularly pertinent for vaginal HIV microbicides, since many lead candidates are poorly water-soluble and where a major goal is the development of a coitally independent, once daily gel product. In this study, we report the use of a non-aqueous silicone elastomer gel for vaginal delivery of the HIV-1 entry inhibitor maraviroc. In vitro rheological, syringeability and retention studies demonstrated enhanced performance for silicone gels compared with a conventional aqueous HEC gel, while testing of the gels in the slug model confirmed a lack of mucosal irritancy. Pharmacokinetic studies following single dose vaginal administration of a maraviroc silicone gel in rhesus macaques showed higher and sustained MVC levels in vaginal fluid, vaginal tissue and plasma compared with a HEC gel containing the same maraviroc loading. The results demonstrate that non-aqueous silicone gels have potential as a formulation platform for coitally independent vaginal HIV microbicides.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864598      PMCID: PMC3220778          DOI: 10.1016/j.jconrel.2011.08.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  49 in total

Review 1.  A vaginal fluid simulant.

Authors:  D H Owen; D F Katz
Journal:  Contraception       Date:  1999-02       Impact factor: 3.375

2.  Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy.

Authors:  J Brown; G Hooper; C J Kenyon; S Haines; J Burt; J M Humphries; S P Newman; S S Davis; R A Sparrow; I R Wilding
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

3.  Design of a semisolid vaginal microbicide gel by relating composition to properties and performance.

Authors:  Alamelu Mahalingam; Eric Smith; Judit Fabian; Festo R Damian; Jennifer J Peters; Meredith R Clark; David R Friend; David F Katz; Patrick F Kiser
Journal:  Pharm Res       Date:  2010-09-15       Impact factor: 4.200

4.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

5.  Assessing microbicide acceptability: a comprehensive and integrated approach.

Authors:  Kathleen M Morrow; Monica S Ruiz
Journal:  AIDS Behav       Date:  2007-06-26

6.  The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test.

Authors:  Marijke M M Dhondt; Els Adriaens; Jens Van Roey; Jean Paul Remon
Journal:  Eur J Pharm Biopharm       Date:  2005-08       Impact factor: 5.571

7.  Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

Authors:  A David Woolfson; R Karl Malcolm; Ryan J Morrow; Clare F Toner; Stephen D McCullagh
Journal:  Int J Pharm       Date:  2006-06-23       Impact factor: 5.875

8.  Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Authors:  Annalene Nel; Shanique Smythe; Katherine Young; Karl Malcolm; Clare McCoy; Zeda Rosenberg; Joseph Romano
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

9.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

10.  Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection.

Authors:  Joachim Brouwers; Kurt Vermeire; Dominique Schols; Patrick Augustijns
Journal:  Virology       Date:  2008-07-07       Impact factor: 3.616

View more
  20 in total

1.  Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.

Authors:  Patricia Fletcher; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

2.  Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.

Authors:  Dan H Barouch; Per Johan Klasse; Jason Dufour; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-14       Impact factor: 11.205

3.  Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.

Authors:  R Karl Malcolm; Deborah Lowry; Peter Boyd; Leslie Geer; Ronald S Veazey; Laurie Goldman; P J Klasse; Robin J Shattock; John P Moore
Journal:  J Antimicrob Chemother       Date:  2013-12-30       Impact factor: 5.790

Review 4.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

5.  Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Authors:  Joshua F Emory; Lauren A Seserko; Mark A Marzinke
Journal:  Clin Chim Acta       Date:  2014-02-19       Impact factor: 3.786

6.  Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

Authors:  R Karl Malcolm; Claire J Forbes; Leslie Geer; Ronald S Veazey; Laurie Goldman; Per Johan Klasse; John P Moore
Journal:  J Antimicrob Chemother       Date:  2012-10-30       Impact factor: 5.790

7.  Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.

Authors:  Susan M Fetherston; Leslie Geer; Ronald S Veazey; Laurie Goldman; Diarmaid J Murphy; Thomas J Ketas; Per Johan Klasse; Sylvain Blois; Paolo La Colla; John P Moore; R Karl Malcolm
Journal:  J Antimicrob Chemother       Date:  2012-10-28       Impact factor: 5.790

8.  Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.

Authors:  Cameron Ball; Kim A Woodrow
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

9.  Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

Authors:  John W McBride; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Peter Boyd; Vicky L Kett; R Karl Malcolm
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.

Authors:  Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm
Journal:  J Pharm Sci       Date:  2014-03-01       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.